SMPD3: Sphingomyelin Phosphodiesterase 3

Key enzyme in ceramide metabolism and bone development

Gene Information Card

Symbol SMPD3
Full Name Sphingomyelin Phosphodiesterase 3
Gene Type Protein-coding
Chromosomal Location 16q22.1
NCBI Gene ID 55512 ncbi.nlm.nih.gov/gene/55512
Ensembl ID ENSG00000103056
UniProt ID Q9NY59
OMIM ID 605777
HGNC ID 14249
Aliases nSMase2, NSMASE2, NSMASE-2, SMD-3

Description

SMPD3 encodes sphingomyelin phosphodiesterase 3, also known as neutral sphingomyelinase 2 (nSMase2). This enzyme catalyzes the hydrolysis of sphingomyelin to ceramide and phosphocholine, playing a critical role in sphingolipid metabolism, cell signaling, apoptosis, and bone mineralization. Mutations in SMPD3 are associated with skeletal dysplasias and developmental disorders.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Osteogenesis Imperfecta Type XXIV Loss-of-function mutations impair ceramide-mediated signaling in osteoblasts, leading to defective bone mineralization and fragility. ClinVar, OMIM
Chondrodysplasia with Platyspondyly Disrupted sphingomyelin metabolism affects chondrocyte differentiation and endochondral ossification. OMIM, PubMed
Hereditary Sensory Neuropathy Type 1 (possible) Altered ceramide levels may impact neuronal membrane stability and signaling. NCBI Gene, UniProt

Expression Profile

Tissue Expression
Tissue nTPM level
Brain 12.5 Medium
Bone Marrow 8.2 Low
Liver 6.1 Low
Kidney 5.4 Low
Lung 4.8 Low
Cell Line Expression
Cell Line nTPM Notes
HeLa 10.3 Moderate expression
HEK293 7.6 Detectable
SH-SY5Y 15.1 High expression in neuronal cells
HepG2 5.9 Low expression
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
c.1003C>T (p.Arg335Ter) Nonsense Rare Loss of function; associated with osteogenesis imperfecta
c.1462G>A (p.Gly488Arg) Missense Rare Impaired catalytic activity
c.1726C>T (p.Arg576Trp) Missense Rare Reduced enzyme stability
Mutation functional classification

Loss of Function (LOF)

Nonsense and missense mutations that reduce or abolish nSMase2 activity lead to impaired ceramide production and bone mineralization defects.

Gain of Function (GOF)

No gain-of-function mutations have been reported for SMPD3.

Dominant Negative (DN)

No dominant-negative mutations have been characterized for SMPD3.

Gene Ontology (GO)

• GO:0004767 – sphingomyelin phosphodiesterase activity • GO:0006685 – sphingomyelin catabolic process
• GO:0006672 – ceramide metabolic process • GO:0005886 – plasma membrane
• GO:0005737 – cytoplasm • GO:0042981 – regulation of apoptotic process

Pathways

Sphingolipid metabolism (KEGG: hsa00600)
Sphingomyelin signaling pathway
Ceramide biosynthesis and signaling

Protein Summary

SMPD3 encodes neutral sphingomyelinase 2 (nSMase2), a 655-amino-acid protein localized to the plasma membrane and cytoplasm. It contains a catalytic domain responsible for sphingomyelin hydrolysis and a sterile alpha motif (SAM) domain involved in protein-protein interactions. nSMase2 is activated by various stimuli including cytokines, oxidative stress, and growth factors, and its activity is essential for ceramide-mediated signaling in bone development, neuronal function, and apoptosis.

Related Products

Product name Cat.No. Species Gene ID
SMPD3 Knockout HEK293 Cell Line EDJ-KQ3537 Human 55512 Details Get a Quote
SMPD3 Knockout HeLa Cell Line EDJ-KQ56593 Human 55512 Details Get a Quote
SMPD3 Knockout A-549 Cell Line EDC90436 Human 55512 Details Get a Quote
SMPD3 Knockout HCT 116 Cell Line EDJ-KQ73539 Human 55512 Details Get a Quote
Displaying Records 1 To 4 Of 4 Records
Contact Us
*
*
*
*
How did you hear about us: